Vice President, Data Science, Genomics, and Bioinformatics

Alexion Pharmaceuticals, Inc.

John Reynders, Ph.D. MBA, is Vice President, Data Sciences, Genomics, and Bioinformatics at Alexion. In his role, Dr. Reynders leads Alexion’s Data Sciences, Genomics, and Bioinformatics (DGB) organization in the design, building, and deployment of DGB solutions spanning R&D, Commercial, Strategy, and Business Development. These solutions include a graph-database of the entire rare-disease landscape annotated with prevalence, severity, competitive intensity, and genetic signature; a genomics-based rare-disease patient prevalence platform to inform licensing/acquisition opportunities; and AI-based phenotype- and genome-driven rare-disease diagnosis decision-support systems.

In parallel to his DGB responsibilities at Alexion, Dr. Reynders also led the R&D strategy, portfolio and project management department, leading efforts across R&D capability strategy, pipeline project management, portfolio optimization, governance, and R&D operating models. Prior to joining Alexion, Dr. Reynders served as CIO of Moderna Therapeutics, where he created a fully cloud-based biotech across all enterprise functions and developed informatics solutions to enable the design of messenger RNA therapeutics. Previously, John served as Vice President of R&D Information at AstraZeneca R&D leading teams in the US, UK, Sweden, Russia, Japan, and China to enable discovery, translational, clinical, pharmaceutical development, and regulatory functions. Before this, John served in leadership roles at Johnson & Johnson including VP Integrative Neuroscience and Biomarkers, Head of Informatics, and VP R&D Information Technology. Previously, John served as Information Officer with Lilly Research Laboratories, VP of Informatics at Celera Genomics, and held roles as Director and Program Manager at the Los Alamos National Laboratory.

Dr. Reynders received a Bachelors, Summa Cum Laude, in Mathematics from Rensselaer Polytechnic Institute, a PhD in Applied and Computational Mathematics from Princeton University, and a Masters of Business Administration from the Northwestern University Kellogg School of Management.


DAY 1 / ‏‏‎ ‎

09:30 AM - 09:55 AM
Genomics View Session

Leveraging AI & Genomics in Discovery of New Drugs/Discovery

Use Case: Setting a new record on the pathway from Patient to Diagnostic to Targeted Treatment in Rare Disease

This use case will delve into a neo-natal intensive care unit case at Rady’s Children hospital wherein a collaborative effort leveraging AI to integrate genomic and clinical record information established a new world record for fastest genomic/AI-based diagnosis. Underlying technologies/capabilities to enable the record – and current next frontiers of research will be discussed.

John Reynders, Vice President, Data Science, Genomics, and Bioinformatics, Alexion Pharmaceuticals, Inc.

Never miss an announcement

/* */